SCHEMBL289813

SCHEMBL289813

O=C(O)c1occc(=O)c1O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.52
LMNA P02545 2/20 0.52
MMP1 P03956 1/20 0.49
MMP3 P08254 1/20 0.49
MMP7 P09237 1/20 0.49
MMP9 P14780 1/20 0.49
MMP8 P22894 1/20 0.49
MMP12 P39900 1/20 0.49
MMP13 P45452 1/20 0.49
KMT2A Q03164 1/20 0.40
APP P05067 3/20 0.38
FTO Q9C0B1 1/20 0.37
DAO P14920 1/20 0.36
ACLY P53396 1/20 0.35
PTPN11 Q06124 2/20 0.34
DUSP3 P51452 1/20 0.34
PTPN5 P54829 1/20 0.34
CTDSP1 Q9GZU7 1/20 0.34
MAPK1 P28482 3/20 0.34
TDP1 Q9NUW8 3/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL146966 0.96 KDM4E (0.48) KDM4ELMNAMMP1MMP3MMP7
SCHEMBL13947098 0.81 KDM4E (0.50) KDM4ELMNAMMP1MMP3MMP7
SCHEMBL25332706 0.81 KDM4E (0.55) KDM4ELMNAMMP1MMP3MMP7
SCHEMBL3796160 0.79 KDM4E (0.48) KDM4ELMNAMMP1MMP3MMP7
SCHEMBL356631 0.79 KDM4E (0.48) KDM4ELMNAMMP1MMP3MMP7
SCHEMBL15287180 0.79 KDM4E (0.48) KDM4ELMNAMMP1MMP3MMP7
SCHEMBL6253172 0.78 CYP1A2 (0.41) KDM4ELMNAMMP1MMP3MMP7
SCHEMBL1109612 0.78 KDM4E (0.47) KDM4ELMNAMMP1MMP3MMP7
SCHEMBL14640707 0.77 KDM4E (0.45) KDM4ELMNAMMP1MMP3MMP7
SCHEMBL23879799 0.76 KDM4E (0.50) KDM4ELMNAMMP1MMP3MMP7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 241 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119638661-A Iron maltol-quercetin eutectic crystal and preparation method thereof 金陵药业股份有限公司 2025-03-18 CN claimed
CN-119638662-A Iron maltol-oxalic acid eutectic crystal and preparation method thereof 金陵药业股份有限公司 2025-03-18 CN claimed
CN-119371388-A Synthesis method of maltol iron crystal form II 珠海保税区丽珠合成制药有限公司 2025-01-28 CN claimed
EP-3666247-B1 DIVIDED CURABLE COMPOSITION MITSUI CHEMICALS INC (JP) 2024-12-18 EP claimed
CN-119102106-A Active antibacterial self-cleaning fabric and preparation method thereof 南通大学 2024-12-10 CN claimed
CN-118978503-A Iron maltol crystal form and preparation method thereof 重庆君药生物医药有限公司 2024-11-19 CN claimed
EP-2938608-B1 SMALL MOLECULE AGONISTS OF NEUROTENSIN RECEPTOR 1 SANFORD BURNHAM MED RES INST (US) 2021-08-04 EP claimed
EP-2712614-B1 SOLVATING SYSTEM AND SEALANT FOR MEDICAL USE MEDTRONIC XOMED INC (US) 2017-11-29 EP claimed
EP-2029232-B1 Antibacterial extracellular polysaccharide solvating system MEDTRONIC XOMED INC (US) 2017-09-20 EP claimed
US-9539233-B2 Gallium formulation for the treatment and prevention of infectious diseases ARIDIS PHARMACEUTICALS INC. (US) 2017-01-10 US claimed
US-20040089101-A1 Copper nanocrystals and methods of producing same WAYNE STATE UNIVERSITY 2004-05-13 US claimed
US-20020193363-A1 Use of nitric oxide scavengers to modulate inflammation and matrix metalloproteinase activity ANORMED INC. (CA) 2002-12-19 US claimed
US-20020049190-A1 Pharmaceutical compositions comprising metal complexes ANORMED INC. (CA) 2002-04-25 US claimed
US-20020045611-A1 Pharmaceutical compositions comprising metal complexes ABRAMS MICHAEL J (US) 2002-04-18 US claimed
EP-1163247-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING METAL COMPLEXES ANORMED INC. (CA) 2001-12-19 EP claimed
US-6284752-B1 ATTENUATION FO NITROGEN OXIDE CONCENTRATION OF A DISEASE ANORMED INC. (CA) 2001-09-04 US claimed
WO-2000056743-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING METAL COMPLEXES ANORMED INC. (CA) 2000-09-28 WO claimed
US-5824673-A COMPLEXES FOR MEDIATION OF LOCALIZED HIGH CONCENTRATIONS OF NITRIC OXIDE IN BODIES JOHNSON MATTHEY PUBLIC LIMTED COMPANY (GB) 1998-10-20 US claimed
EP-0714294-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING METAL COMPLEXES Johnson Matthey PLC (GB) 1996-06-05 EP claimed
WO-1995005814-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING METAL COMPLEXES JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) 1995-03-02 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020049190-A1 Pharmaceutical compositions comprising metal complexes CFD, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, F12 KDM4E 2866/4885LMNA 645/4885MMP1 4649/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.